Development of a Novel Peptide Nanoparticle Inhibitor for Human CCR3/Eotaxin-Mediated Eosinophil Migration

For unclear reasons, a small molecule CCR3 antagonist recently failed to show clinical efficacy in asthma, We have sought to develop novel peptide nanoparticle-based inhibitors of CCR3 that reduce signaling, chemotaxis and recruitment of multiple immune cells in allergic inflammation.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2015-02, Vol.135 (2), p.AB160-AB160
Hauptverfasser:	Laffey, Kimberly G., BSc, Garnier, Boris, PhD, Hitchinson, Ben, BSc, Tarasova, Nadya, PhD, Gaponenko, Vadim, PhD, Ackerman, Steven J., PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Asthma Chemokines Medical research Nanoparticles Peptides
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	For unclear reasons, a small molecule CCR3 antagonist recently failed to show clinical efficacy in asthma, We have sought to develop novel peptide nanoparticle-based inhibitors of CCR3 that reduce signaling, chemotaxis and recruitment of multiple immune cells in allergic inflammation.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2014.12.1463